Arcutis Biotherapeutics vs Cormedix
Arcutis Biotherapeutics is the larger business, with $376m of revenue in fiscal 2025 against $312m for Cormedix (1.2 times as much). Cormedix grew faster (617.0% against 91.3%). Cormedix kept more of each dollar of sales as profit: a net margin of 52.3% against -4.3%.
| Latest fiscal year | Arcutis BiotherapeuticsARQT, 2025 | CormedixCRMD, 2025 |
|---|---|---|
| Revenue | $376m | $312m |
| Revenue growth | 91.3% | 617.0% |
| Net income | −$16.1m | $163m |
| Operating margin | -3.3% | — |
| Net margin | -4.3% | 52.3% |
| Return on equity | -9.3% | 66.6% |
| Free cash flow | −$6.3m | $173m |
| Cash | $42.9m | $145m |
| Total debt | $109m | $144,626 |
| Debt to equity | 57.5% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 354 | 191 |
| Market value | $4.02bn | $428m |
| Price vs our value range | — | Below our value range |
| Moat score | — | 7 (Weak) |
| Insider trades, 12 months | 0 buys, 77 sales | 0 buys, 8 sales |